Assessing the cardiovascular safety of diabetes therapies

被引：87

作者：

Goldfine, Allison B. ^{[1
,2
]}

机构：

[1] Joslin Diabet Ctr, Sect Clin Res, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

关键词：

D O I：

10.1056/NEJMp0805758

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1092 / 1095

页数：5

共 5 条

[1] Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
[2] KLIMT CR, 1970, DIABETES, V19, P747
[3] Coronary heart disease outcomes in patients receiving antidiabetic agents
McAfee, Andrew T.
Koro, Carol
Landon, Joan
Ziyadeh, Najat
Walker, Alexander M.
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (07) : 711 - 725
[4] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007)
Nissen, Steven E.
Wolski, Kathy
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) : 2457 - 2471
[5] Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Patel, Anushka
MacMahon, Stephen
Chalmers, John
Neal, Bruce
Billot, Laurent
Woodward, Mark
Marre, Michel
Cooper, Mark
Glasziou, Paul
Grobbee, Diederick
Hamet, Pavel
Harrap, Stephen
Heller, Simon
Liu, Lisheng
Mancia, Giuseppe
Mogensen, Carl Erik
Pan, Changyu
Poulter, Neil
Rodgers, Anthony
Williams, Bryan
Bompoint, Severine
de Galan, Bastiaan E.
Joshi, Rohina
Travert, Florence
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) : 2560 - 2572